These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Prevalence of N-Methyl-d-Aspartate Receptor antibody (NMDAR-Ab) encephalitis in patients with first episode psychosis and treatment resistant schizophrenia on clozapine, a population based study. Kelleher E; McNamara P; Dunne J; Fitzmaurice B; Heron EA; Whitty P; Walsh R; Mooney C; Hogan D; Conlon N; Gill M; Vincent A; Doherty CP; Corvin A Schizophr Res; 2020 Aug; 222():455-461. PubMed ID: 32499165 [TBL] [Abstract][Full Text] [Related]
6. The validity of atypical psychosis diagnostic criteria to detect anti-NMDA receptor encephalitis with psychiatric symptoms. Hinotsu K; Miyaji C; Yada Y; Kawai H; Sakamoto S; Okahisa Y; Tsutsui K; Kanbayashi T; Tanaka K; Takao S; Kishi Y; Takaki M; Yamada N Schizophr Res; 2022 Oct; 248():292-299. PubMed ID: 36130472 [TBL] [Abstract][Full Text] [Related]
7. [Review of the psychiatric aspects of anti-NMDA (N-methyl-D-aspartic acid) receptor encephalitis, case report, and our plans for a future study]. Herman L; Zsigmond IR; Peter L; Rethelyi JM Neuropsychopharmacol Hung; 2016 Dec; 18(4):199-208. PubMed ID: 28259863 [TBL] [Abstract][Full Text] [Related]
8. Management of psychiatric symptoms in anti-NMDAR encephalitis: a case series, literature review and future directions. Kuppuswamy PS; Takala CR; Sola CL Gen Hosp Psychiatry; 2014; 36(4):388-91. PubMed ID: 24731834 [TBL] [Abstract][Full Text] [Related]
9. Anti-NMDA receptor encephalitis: a case study and illness overview. Ford B; McDonald A; Srinivasan S Drugs Context; 2019; 8():212589. PubMed ID: 31516531 [TBL] [Abstract][Full Text] [Related]